<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03783052</url>
  </required_header>
  <id_info>
    <org_study_id>S60930</org_study_id>
    <nct_id>NCT03783052</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Physiological Conditions After Bariatric Surgery</brief_title>
  <acronym>GASTON</acronym>
  <official_title>Gastrointestinal Physiological Conditions After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the years, obesity has become a major public health concern. The increasing rates of
      obesity are associated with an enhanced demand for weight-loss with bariatric surgery as a
      treatment option. Bariatric surgery procedures alter the anatomical structure of the
      gastrointestinal tract, which contributes to the postoperative weight loss. However, it is
      not sure how the anatomical alterations affect the gastrointestinal physiology including
      gastrointestinal pH, gastric emptying, intestinal transit time and concentration of enzymes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the visit in the obesity clinic, eligible patients will be approached for
      participation by the sub-investigator. Interested patients will receive information regarding
      the study and receive the information sheet containing the informed consent form. After
      signing the informed consent form, volunteers will be invited to come to the clinical
      research center:

        -  Healthy volunteers: Gastrointestinal physiology will be analyzed during two visits using
           a telemetric capsule. During the first visit, the physiological conditions of interest
           will be analysed in fasted state using the telemetric capsule. During the second visit,
           the physiological conditions of interest will be analysed in fed state using the
           telemetric capsule.

        -  Obese volunteers: Gastrointestinal physiology will be analyzed during two visits using a
           telemetric capsule. During the first visit, the physiological conditions of interest
           will be analysed in fasted state using the telemetric capsule. During the second visit,
           the physiological conditions of interest will be analysed in fed state using the
           telemetric capsule.

        -  Volunteers after Sleeve Gastrectomy: Gastrointestinal physiology will be analyzed during
           three visits using a telemetric capsule, scintigraphy and via the collection of
           gastrointestinal samples. During the first visit, the physiological conditions of
           interest will be analysed in fasted state using the telemetric capsule. During the
           second visit, gastrointestinal samples will be collected at the level of the sleeve, the
           duodenum and jejunum via aspiration through multiple lumen catheters in fasted and fed
           state. During the third visit, gastric emptying will be observed via scintigraphy in fed
           state.

        -  Volunteers after Roux-en-Y gastric Bypass: Gastrointestinal physiology will be analyzed
           during three visits using a telemetric capsule, scintigraphy and via the collection of
           gastrointestinal samples. During the first visit, the physiological conditions of
           interest will be analysed in fasted state using the telemetric capsule. During the
           second visit, gastrointestinal samples will be collected at the level of the pouch, the
           Roux limb and the common limb via aspiration through multiple lumen catheters in fasted
           and fed state. During the third visit, gastric emptying will be observed via
           scintigraphy in fed state.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Temperature</measure>
    <time_frame>0-7 days</time_frame>
    <description>Gastrointestinal Temperature (Â°C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal pH</measure>
    <time_frame>0-7 days</time_frame>
    <description>Gastrointestinal pH (pH values)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Pressure</measure>
    <time_frame>0-7 days</time_frame>
    <description>Gastrointestinal Pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of bile acids</measure>
    <time_frame>1 day</time_frame>
    <description>Concentration of bile acids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric emptying time</measure>
    <time_frame>2 hours</time_frame>
    <description>Gastric emptying time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal motility</measure>
    <time_frame>0-7 days</time_frame>
    <description>Contractions per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal transit times</measure>
    <time_frame>0-7 days</time_frame>
    <description>Gastric Emptying Time (hours), Small Bowel Transit Time (hours), Colonic Transit Time (hours) and Whole Gut Transit Time (hours)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 Obese Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y Gastric Bypass patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 volunteers with a Roux-en-Y Gastric Bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleeve Gastrectomy patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 volunteers with a Sleeve Gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartPill in fasted state</intervention_name>
    <description>SmartPill administration in fasted state</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Obese volunteers</arm_group_label>
    <arm_group_label>Roux-en-Y Gastric Bypass patients</arm_group_label>
    <arm_group_label>Sleeve Gastrectomy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartPill in fed state</intervention_name>
    <description>SmartPill administration in fed state</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Obese volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aspiration</intervention_name>
    <description>Aspiration of gastrointestinal samples in fasted and fed state</description>
    <arm_group_label>Roux-en-Y Gastric Bypass patients</arm_group_label>
    <arm_group_label>Sleeve Gastrectomy patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gastric emptying scintigraphy</intervention_name>
    <description>Gastric emptying scintigraphy in fed state</description>
    <arm_group_label>Roux-en-Y Gastric Bypass patients</arm_group_label>
    <arm_group_label>Sleeve Gastrectomy patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 18 years or older

        Exclusion Criteria:

          -  History of gastric ulcers

          -  Disorders of swallowing

          -  Suspected strictures, fistulas or physiological GI obstruction.

          -  GI surgery within past three months

          -  Severe dysphagia to food or pills

          -  Crohns disease or diverticulitis

          -  Use of implanted or portable electro-mechanical medical devices

          -  Known intolerance to the SmartPill device

          -  Known food allergies to any component of the meal

          -  History of multiple bariatric surgeries

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Van der Schueren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven, Department of Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nele Steenackers</last_name>
    <phone>0032 16 34 49 13</phone>
    <email>nele.steenackers@kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Steenackers</last_name>
      <phone>0032 16 34 49 13</phone>
      <email>nele.steenackers@kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

